Protein & Cell >

2021 , Vol. 12 >Issue 2: 84 - 88

DOI: https://doi.org/10.1007/s13238-020-00806-7

COMMENTARY

Pan-coronavirus fusion inhibitors as the hope for today and tomorrow

  • Xinling Wang 1 ,
  • Shuai Xia 1 ,
  • Yun Zhu 2 ,
  • Lu Lu , 1 ,
  • Shibo Jiang , 1
Expand
  • 1. Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai 200032, China
  • 2. National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China

Accepted date: 09 Oct 2020

Published date: 15 Feb 2021

Copyright

2020 The Author(s)
Fold

Cite this article

Xinling Wang , Shuai Xia , Yun Zhu , Lu Lu , Shibo Jiang . Pan-coronavirus fusion inhibitors as the hope for today and tomorrow[J]. Protein & Cell, 2021 , 12(2) : 84 -88 . DOI: 10.1007/s13238-020-00806-7

References

Publishing order | Descend order by publishing year | Descend order by cited within
1
Bi W, Xu W, Cheng L, Xue J, Wang Q, Yu F, Xia S, Wang Q, Li G, Qin C (2019) IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies. PLoS Pathog 15:e1008082

DOI

2
Cui J, Li F, Shi ZL (2019) Origin and evolution of pathogenic coronaviruses. Nature Reviews Microbiology 17:181–192

DOI

3
Fosgerau K, Hoffmann T (2015) Peptide therapeutics: current status and future directions. Drug Discov Today 20:122–128

DOI

4
Graham RL, Donaldson EF, Baric RS (2013) A decade after SARS: strategies for controlling emerging coronaviruses. Nature Reviews Microbiology 11:836–848

DOI

5
Hamburger AE, Kim S, Welch BD,Kay MS (2005) Steric accessibility of the HIV-1 gp41 N-trimer region. J Biol Chem 280:12567–12572

DOI

6
Hollmann A, Matos PM, Augusto MT, Castanho MARB, Santos NC (2013) Conjugation of cholesterol to HIV-1 fusion inhibitor C34 increases peptide-membrane interactions potentiating its action. Plos ONE 8:e60302

DOI

7
Holmes KV (2003) SARS coronavirus: a new challenge for prevention and therapy. J Clin Invest 111:1605–1609

DOI

8
Jiang S, Du L, Shi Z (2020) An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. Emerg Microbes Infect 9:275–277

DOI

9
Jiang S, Lin K, Strick N, dlx AR (1993) Hiv-1 inhibition by a peptide. Nature 365:113

DOI

10
Kleine-Weber H, Elzayat MT, Wang LS, Graham BS, Muller MA, Drosten C, Pohlmann S, Hoffmann M (2019) Mutations in the Spike Protein of Middle East respiratory syndrome coronavirus transmitted in Korea increase resistance to antibody-mediated neutralization. J Virol 93:e01381

DOI

11
Konca C, Korukluoglu G, Tekin M, Almis H, Bucak IH, Uygun H, Altas AB, Bayrakdar F (2017) The First Infant Death Associated with Human Coronavirus Nl63 Infection. Pediatr Infect Dis J 36:231–233

DOI

12
Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, Xiong H, Farmar J, Debnath AK, Tien P (2004) Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 363:938–947

DOI

13
Lu L, Liu Q, Zhu Y, Chan KH, Qin L, Li Y, Wang Q, Chan JF, Du L, Yu F (2014) Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun 5:3067

DOI

14
Morfopoulou S, Brown JR, Davies EG, Anderson G, Virasami A, Qasim W, Chong WK, Hubank M, Plagnol V, Desforges M (2016) Human coronavirus OC43 associated with fatal encephalitis. New Engl J Med 375:497–498

DOI

15
Nielsen DS, Shepherd NE, Xu WJ, Lucke AJ, Stoermer MJ, Fairlie DP (2017) Orally absorbed cyclic peptides. Chem Rev 117:8094–8128

DOI

16
Ou J, Zhou Z, Dai R, Zhang J,Lan W, Zhao S, Wu J, Donald Seto, Cui L, Zhang G (2020) Emergence of RBD mutations in circulating SARS-CoV-2 strains enhancing the structural stability and human ACE2 receptor affinity of the spike protein. Preprint at.https://doi.org/10.1101/2020.03.15.991844

DOI

17
Veiga A, Martins LG, Riediger I, Mazetto A, Debur MDC, Gregianini TS (2020) More than just a common cold: Endemic coronaviruses OC43, HKU1, NL63, and 229E associated with severe acute respiratory infection and fatality cases among healthy adults. J Med Virol.https://doi.org/10.1002/jmv.26362

DOI

18
Wang C, Hua C, Xia S, Li W, Lu L, Jiang S (2019) Combining a fusion inhibitory peptide targeting the MERS-CoV S2 protein HR1 domain and a neutralizing antibody specific for the S1 protein receptor-binding domain (RBD) showed potent synergism against pseudotyped MERS-CoV with or without mutations in RBD. Viruses-Basel 11:31

DOI

19
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269–271

DOI

20
Wong AHM, Tomlinson ACA, Zhou DX, Satkunarajah M, Chen K, Sharon C, Desforges M, Talbot PJ, Rini JM (2017) Receptorbinding loops in alphacoronavirus adaptation and evolution. Nat Commun 8:1735

DOI

21
Wu Y, Li C, Xia S, Tian X, Kong Y, Wang Z, Gu C, Zhang R, Tu C, Xie Y (2020) Identification of human single-domain antibodies against SARS-CoV-2. Cell Host Microbe 27(891–898):e895

DOI

22
Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, Ying T, Liu S, Shi Z, Jiang S (2020a) Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol 17:765–767

DOI

23
Xia S, Liu M, Wang C, Xu W,Lan Q, Feng S, Qi F, Bao L, Du L, Liu S (2020b) Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res 30:343–355

DOI

24
Xia S, Yan L, Xu W, Agrawal AS, Algaissi A, Tseng CK, Wang Q, Du L, Tan W, Wilson IA (2019) A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv 5: eaav4580

DOI

Options
Outlines

/

〈 〉